These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29424785)

  • 1. Bone density, microarchitecture, and tissue quality after 1 year of treatment with tenofovir disoproxil fumarate.
    Güerri-Fernández R; Lerma-Chippirraz E; Fernandez Marron A; García-Giralt N; Villar-García J; Soldado-Folgado J; González-Mena A; Trenchs-Rodríguez M; Guelar A; Díez-Pérez A; Brown TT; Knobel H
    AIDS; 2018 Apr; 32(7):913-920. PubMed ID: 29424785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
    Güerri-Fernández R; Molina-Morant D; Villar-García J; Herrera S; González-Mena A; Guelar A; Trenchs-Rodríguez M; Díez-Pérez A; Knobel H
    J Acquir Immune Defic Syndr; 2017 Jul; 75(3):322-327. PubMed ID: 28418990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    Hoy JF; Richardson R; Ebeling PR; Rojas J; Pocock N; Kerr SJ; Martinez E; Carr A;
    AIDS; 2018 Sep; 32(14):1967-1975. PubMed ID: 29927785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals.
    Guan W; Pan W; Yu W; Cao W; Lin Q; Zhang Z; Song X; Li Y; Tian J; Xu Y; Li T; Hsieh E
    Arch Osteoporos; 2021 Feb; 16(1):41. PubMed ID: 33624129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
    Zhang Z; Lin Q; Xu Y; Guan W; Song X; Li Y; Zhang Y; Li T; Yu W
    Arch Osteoporos; 2023 Apr; 18(1):48. PubMed ID: 37041320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabecular bone scores in young HIV-infected men: a matched case-control study.
    Kim YJ; Kang KY; Shin J; Jun Y; Kim SI; Kim YR
    BMC Musculoskelet Disord; 2020 Feb; 21(1):94. PubMed ID: 32041580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA; Lupo S; Parks D; Poggio MC; De Wet J; Kahl LP; Angelis K; Wynne B; Vandermeulen K; Gartland M; Cupo M; Aboud M;
    AIDS; 2018 Feb; 32(4):477-485. PubMed ID: 29239893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
    Giacomet V; Maruca K; Ambrosi A; Zuccotti GV; Mora S
    Int J Antimicrob Agents; 2017 Sep; 50(3):365-370. PubMed ID: 28689877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in bone quality after switching from a TDF to a TAF based ART: A pilot randomized study.
    Soldado-Folgado J; Rins-Lozano O; Arrieta-Aldea I; Gonzále-Mena A; Cañas-Ruano E; Knobel H; Garcia-Giralt N; Güerri-Fernández R
    Front Endocrinol (Lausanne); 2023; 14():1076739. PubMed ID: 37051195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy.
    Guan WM; Pan W; Yu W; Cao W; Lin Q; Zhang ZZ; Song XJ; Li YL; Tian JP; Xu Y; Li TS; Hsieh E
    J Orthop Translat; 2021 Jul; 29():72-77. PubMed ID: 34094860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone density, microarchitecture, and material strength in chronic kidney disease patients at the time of kidney transplantation.
    Pérez-Sáez MJ; Herrera S; Prieto-Alhambra D; Vilaplana L; Nogués X; Vera M; Redondo-Pachón D; Mir M; Güerri R; Crespo M; Díez-Pérez A; Pascual J
    Osteoporos Int; 2017 Sep; 28(9):2723-2727. PubMed ID: 28497224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation status in HIV-positive individuals correlates with changes in bone tissue quality after initiation of ART.
    Lerma-Chippirraz E; Pineda-Moncusí M; González-Mena A; Soldado-Folgado J; Knobel H; Trenchs-Rodríguez M; Díez-Pérez A; Brown TT; García-Giralt N; Güerri-Fernández R
    J Antimicrob Chemother; 2019 May; 74(5):1381-1388. PubMed ID: 30768163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine.
    Soldado-Folgado J; Lerma-Chippirraz E; Arrieta-Aldea I; Bujosa D; García-Giralt N; Pineda-Moncusi M; Trenchs-Rodríguez M; Villar-García J; González-Mena A; Díez-Pérez A; Brown TT; Knobel H; Güerri-Fernández R
    J Antimicrob Chemother; 2020 Oct; 75(10):2998-3003. PubMed ID: 32710105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
    PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
    Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.
    Kalayjian RC; Albert JM; Cremers S; Gupta SK; McComsey GA; Klingman KL; Fichtenbaum CJ; Brown TT; Taiwo BO;
    AIDS; 2018 Nov; 32(17):2517-2524. PubMed ID: 30134291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Harris DR; Price G; Baker A; Meyer WA; Wilson CM; Hazra R; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2018 Jan; 66(2):220-228. PubMed ID: 29020329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.